The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High atezolizumab antidrug antibody levels are associated with unfavorable clinical outcomes and diminished T cell responses following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
 
Hong Jae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Green Cross; Menarini; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; Sillajen
Research Funding - Boryung Pharmaceuticals; Dong-A ST; Roche
 
Chan Kim
Honoraria - BMS; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - BMS; MSD; Oncocross; ONEGENE BIOTECHNOLOGY; Ono Pharmaceutical; Panolos Bioscience
Research Funding - Boryung; CHA vaccine institute; Dong-A ST; Oncocross; Roche (Inst); Samyang; Virocure
 
Hannah Yang
No Relationships to Disclose
 
Ilhwan Kim
No Relationships to Disclose
 
Beodeul Kang
No Relationships to Disclose
 
Hyeyeong Kim
No Relationships to Disclose
 
Hyunho Kim
No Relationships to Disclose
 
Won Suk Lee
No Relationships to Disclose
 
Sanghoon Jung
No Relationships to Disclose
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Jaekyung Cheon
No Relationships to Disclose